We’ve recently updated our valuation analysis.

Exagen Valuation

Is XGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XGN?

Other financial metrics that can be useful for relative valuation.

XGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.2x
Enterprise Value/EBITDA-0.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does XGN's PS Ratio compare to its peers?

The above table shows the PS ratio for XGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13.1x
SQZ SQZ Biotechnologies
2.1x75.2%US$45.6m
FNCH Finch Therapeutics Group
27.7x83.3%US$46.0m
DYAI Dyadic International
17.1x30.6%US$42.8m
ISR Isoray
5.5xn/aUS$54.8m
XGN Exagen
0.9x23.1%US$40.6m

Price-To-Sales vs Peers: XGN is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (13.1x).


Price to Earnings Ratio vs Industry

How does XGN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.2%
n/an/an/a

Price-To-Sales vs Industry: XGN is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Biotechs industry average (12x)


Price to Sales Ratio vs Fair Ratio

What is XGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: XGN is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).


Share Price vs Fair Value

What is the Fair Price of XGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XGN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.43
US$7.50
+208.6%
11.5%US$9.00US$7.00n/a4
Nov ’23US$2.44
US$10.50
+330.3%
20.8%US$14.00US$8.00n/a4
Oct ’23US$2.71
US$12.25
+352.0%
18.6%US$15.00US$10.00n/a4
Sep ’23US$4.37
US$12.25
+180.3%
18.6%US$15.00US$10.00n/a4
Aug ’23US$7.76
US$16.40
+111.3%
11.9%US$19.00US$13.00n/a5
Jul ’23US$6.05
US$16.40
+171.1%
11.9%US$19.00US$13.00n/a5
Jun ’23US$5.00
US$16.40
+228.0%
11.9%US$19.00US$13.00n/a5
May ’23US$6.10
US$18.00
+195.1%
11.7%US$20.00US$15.00n/a5
Apr ’23US$7.74
US$18.00
+132.6%
11.7%US$20.00US$15.00n/a5
Mar ’23US$7.12
US$24.20
+239.9%
14.4%US$30.00US$20.00n/a5
Feb ’23US$9.35
US$24.20
+158.8%
14.4%US$30.00US$20.00n/a5
Jan ’23US$11.63
US$24.40
+109.8%
14.1%US$30.00US$20.00n/a5
Dec ’22US$9.73
US$24.40
+150.8%
14.1%US$30.00US$20.00US$2.635
Nov ’22US$12.11
US$25.00
+106.4%
17.9%US$33.00US$20.00US$2.445
Oct ’22US$14.08
US$25.00
+77.6%
17.9%US$33.00US$20.00US$2.715
Sep ’22US$13.80
US$25.00
+81.2%
17.9%US$33.00US$20.00US$4.375
Aug ’22US$11.92
US$26.20
+119.8%
13.5%US$33.00US$23.00US$7.765
Jul ’22US$15.21
US$26.20
+72.3%
13.5%US$33.00US$23.00US$6.055
Jun ’22US$13.76
US$26.20
+90.4%
13.5%US$33.00US$23.00US$5.005
May ’22US$16.86
US$26.60
+57.8%
12.3%US$33.00US$24.00US$6.105
Apr ’22US$17.50
US$27.00
+54.3%
13.1%US$33.00US$24.00US$7.744
Mar ’22US$19.56
US$24.25
+24.0%
18.5%US$32.00US$21.00US$7.124
Feb ’22US$15.73
US$24.25
+54.2%
18.5%US$32.00US$21.00US$9.354
Jan ’22US$13.20
US$23.75
+79.9%
20.3%US$32.00US$20.00US$11.634
Dec ’21US$14.26
US$23.75
+66.5%
20.3%US$32.00US$20.00US$9.734

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies